Magnolia Medical launches new technology-enabled service for sepsis
Summary
The Magnolia Analytics platform is a response to the need for robust quantification of the clinical and economic value created by reducing blood culture contamination. This aligns with the recent CDC guidelines, which emphasise the importance of accurate sepsis testing for patient safety and hospital financial efficiency. “The continued adoption of Steripath and Magnolia Medical’s Mission to ZERO programme at nearly 500 hospitals and healthcare systems to date across the US speaks to the impact of our technology solution. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Macedonia, The Former Yugoslav Republic of Tick here to opt out of curated industry news, reports, and event updates from Medical Device Network. Bullington added: “Magnolia Analytics is an essential part of our Mission to ZERO solution, providing clinicians with confidence regarding the accuracy of blood culture results while giving our customers peace of mind that they will continually achieve validated, measurable, and sustained returns on their Steripath investment.” Last year, Magnolia Medical secured 510(k) clearance from the US Food and Drug Administration for 19 new Steripath Micro configurations within its Initial Specimen Diversion Device product family.